Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800–1808. Blood. 2018;131(5):587–8. https://doi.org/10.1182/blood-2017-11-817775

Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531–44. https://doi.org/10.1056/NEJMoa1707447.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839–52. https://doi.org/10.1016/s0140-6736(20)31366-0.

Article  CAS  PubMed  Google Scholar 

Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22(10):1403–15. https://doi.org/10.1016/s1470-2045(21)00375-2.

Article  CAS  PubMed  Google Scholar 

Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022;386(7):640–54. https://doi.org/10.1056/NEJMoa2116133.

Article  CAS  PubMed  Google Scholar 

Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625–38. https://doi.org/10.1016/j.bbmt.2018.12.758.

Article  CAS  PubMed  Google Scholar 

Sesques P, Kirkwood AA, Kwon M, Rejeski K, Jain MD, Di Blasi R, et al. Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma. J Hematol Oncol. 2024;17(1):61. https://doi.org/10.1186/s13045-024-01579-w.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pennisi M, Sanchez-Escamilla M, Flynn JR, Shouval R, Alarcon Tomas A, Silverberg ML, et al. Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells. Blood Adv. 2021;5(17):3397–406. https://doi.org/10.1182/bloodadvances.2020003885.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Greenbaum U, Strati P, Saliba RM, Torres J, Rondon G, Nieto Y, et al. CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. Blood Adv. 2021;5(14):2799–806. https://doi.org/10.1182/bloodadvances.2021004575.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gust J, Taraseviciute A, Turtle CJ. Neurotoxicity associated with CD19-targeted CAR-T cell therapies. CNS Drugs. 2018;32(12):1091–101. https://doi.org/10.1007/s40263-018-0582-9.

Article  PubMed  PubMed Central  Google Scholar 

Galli E, Di Blasi R, Di Rocco A, Cristinelli C, Pansini I, Bommier C, et al. Routine prophylaxis with levetiracetam offers no benefit in CD19 CAR-T for LBCL: a multicenter propensity-matched study. Blood Adv. 2025;9(21):5501–9. https://doi.org/10.1182/bloodadvances.2025017378.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guo Z, Ding Y, Wang M, Zhai Q, Liu J, Du Q. Comparing the differences in adverse events among chimeric antigen receptor T-cell therapies: a real-world pharmacovigilance study. Pharm (Basel). 2024. https://doi.org/10.3390/ph17081025.

Article  Google Scholar 

Cohen AD, Parekh S, Santomasso BD, Gállego Pérez-Larraya J, van de Donk N, Arnulf B, et al. Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer J. 2022;12(2):32. https://doi.org/10.1038/s41408-022-00629-1.

Article  PubMed  PubMed Central  Google Scholar 

Van Oekelen O, Aleman A, Upadhyaya B, Schnakenberg S, Madduri D, Gavane S, et al. Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy. Nat Med. 2021;27(12):2099–103. https://doi.org/10.1038/s41591-021-01564-7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schneider S, Aamodt WW, Pruitt AA, Berger JR. Parkinsonism associated with anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy. Mov Disord Clin Pract. 2024;11(12):1625–8. https://doi.org/10.1002/mdc3.14239.

Article  PubMed  PubMed Central  Google Scholar 

Sanderson JB, Lin YH, Su K, Wang Y, Portuguese A, Gauthier J, et al. Treatment-emergent parkinsonism in four patients treated with chimeric antigen receptor T-cell therapy. Mov Disord Clin Pract. 2025. https://doi.org/10.1002/mdc3.70452.

Article  PubMed  PubMed Central  Google Scholar 

Zhu K, Singh R, Gerson J. Parkinsonism after treatment with anti-CD19 CAR-T: case report, institutional data review, and pharmacovigilance analysis of the FDA adverse event reporting system database. Blood. 2025;146:4144.

Article  Google Scholar 

Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022;399(10343):2294–308. https://doi.org/10.1016/s0140-6736(22)00662-6.

Article  CAS  PubMed  Google Scholar 

Frey N, Porter D. Cytokine release syndrome with chimeric antigen receptor T cell therapy. Biol Blood Marrow Transplant. 2019;25(4):e123–7. https://doi.org/10.1016/j.bbmt.2018.12.756.

Article  CAS  PubMed  Google Scholar 

Rubin DB, Danish HH, Ali AB, Li K, LaRose S, Monk AD, et al. Neurological toxicities associated with chimeric antigen receptor T-cell therapy. Brain. 2019;142(5):1334–48. https://doi.org/10.1093/brain/awz053.

Article  PubMed  Google Scholar 

Santomasso BD, Nastoupil LJ, Adkins S, Lacchetti C, Schneider BJ, Anadkat M, et al. Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline. J Clin Oncol. 2021;39(35):3978–92. https://doi.org/10.1200/jco.21.01992.

Article  CAS  PubMed  Google Scholar 

Wronski M, Wesselingh R, Kazzi C, Seery N, Ko K, Li J, et al. Neurotoxicity associated with chimeric antigen receptor T-cell therapy. J Neuroimmunol. 2025;407:578717. https://doi.org/10.1016/j.jneuroim.2025.578717.

Article  CAS  PubMed  Google Scholar 

Gust J, Hay KA, Hanafi LA, Li D, Myerson D, Gonzalez-Cuyar LF, et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 2017;7(12):1404–19. https://doi.org/10.1158/2159-8290.cd-17-0698.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Santomasso BD, Park JH, Salloum D, Riviere I, Flynn J, Mead E, et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov. 2018;8(8):958–71. https://doi.org/10.1158/2159-8290.cd-17-1319.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ransohoff RM, Kivisäkk P, Kidd G. Three or more routes for leukocyte migration into the central nervous system. Nat Rev Immunol. 2003;3(7):569–81. https://doi.org/10.1038/nri1130.

Article  CAS  PubMed  Google Scholar 

Brandl S, Reindl M. Blood-brain barrier breakdown in neuroinflammation: current in vitro models. Int J Mol Sci. 2023. https://doi.org/10.3390/ijms241612699.

Article  PubMed  PubMed Central  Google Scholar 

Parker KR, Migliorini D, Perkey E, Yost KE, Bhaduri A, Bagga P, et al. Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies. Cell. 2020;183(1):126-42.e17. https://doi.org/10.1016/j.cell.2020.08.022.

Article  CAS  PubMed  PubMed Central